Back to top
more

AxoGen (AXGN)

(Delayed Data from NSDQ)

$6.63 USD

6.63
421,184

+0.11 (1.69%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $6.62 -0.01 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for AXGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for AxoGen, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 37 55 90 111 103
Receivables 25 22 18 18 17
Notes Receivable 0 0 0 0 0
Inventories 23 19 17 13 14
Other Current Assets 3 2 2 4 2
Total Current Assets 88 98 127 145 135
Net Property & Equipment 89 79 63 38 15
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 5 4 3 2 2
Deposits & Other Assets 0 0 0 0 0
Total Assets 197 195 208 201 155
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 29 22 22 22 19
Current Portion Long-Term Debt 0 0 0 0 2
Current Portion Capital Leases 2 1 2 1 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 30 24 24 23 21
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 47 46 45 32 2
Non-Current Capital Leases 21 20 21 21 0
Other Non-Current Liabilities 3 5 6 3 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 101 94 95 78 22
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 377 360 343 326 312
Retained Earnings -281 -260 -231 -204 -180
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 96 101 113 123 132
Total Liabilities & Shareholder's Equity 197 195 208 201 155
Total Common Equity 96 101 113 123 132
Shares Outstanding 43.00 42.20 41.50 40.60 39.40
Book Value Per Share 2.22 2.39 2.71 3.03 3.35

Fiscal Year End for AxoGen, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 37 39 41 44
Receivables NA 25 23 22 22
Notes Receivable NA 0 0 0 0
Inventories NA 23 23 21 20
Other Current Assets NA 3 3 3 2
Total Current Assets NA 88 87 86 89
Net Property & Equipment NA 89 89 87 83
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 5 4 4 4
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 197 195 192 189
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 29 26 23 20
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 2 1 1 1
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 30 27 24 21
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 47 46 46 46
Non-Current Capital Leases NA 21 20 20 20
Other Non-Current Liabilities NA 4 4 5
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 101 97 94 92
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 377 375 370 364
Retained Earnings NA -281 -277 -273 -267
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 96 98 97 98
Total Liabilities & Shareholder's Equity NA 197 195 192 189
Total Common Equity 0 96 98 97 98
Shares Outstanding 43.60 43.00 42.90 42.80 42.60
Book Value Per Share 0.00 2.22 2.28 2.27 2.29